About IgGenix

IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.

Elite School Alumni
Company Highlights
Year Founded

2019

icon-altEmployees

11

Location (HQ)

USA

Since Last Funding

1 year 7 months

Monthly Website Visitors

1.5K

icon-altTotal Investment Amt

$75M

Last Funding Round

Series B

icon-altMoM Headcount Growth

9.9%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Health Care

Biotechnology

Biotechnology Research

Medical